Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Schizophrenia and bipolar disorder are severe mental illnesses which are highly prevalent worldwide. Risperidone and Paliperidone are treatments for either illnesses, but their efficacy compared to other antipsychotics and growing reports of hormonal imbalances continue to raise concerns. As existing evidence on both antipsychotics are solely based on aggregate data, we aimed to assess the benefits and harms of Risperidone and Paliperidone in the treatment of patients with schizophrenia or bipolar disorder, using individual participant data (IPD), clinical study reports (CSRs) and publicly available sources (journal publications and trial registries).

More information Original publication

DOI

https://doi.org/10.1186/s12916-021-02062-w

Type

Journal article

Journal

BMC Medicine

Issue

195

Publisher

BMC

Publication Date

25/08/2021

Volume

19

Addresses

Workstream 3, ESWG, PI Maria Panagioti

Keywords

Antipsychotics, Risperidone, Paliperidone, Schizophrenia, Bipolar disorder, Individual participant data, Meta-analysis, Clinical study reports